These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19381278)

  • 21. [Therapeutic use of tetrabenazine].
    López Del Val LJ; López-García E; Martínez-Martínez L; Santos-Lasaosa S
    Rev Neurol; 2009 May 16-31; 48(10):523-33. PubMed ID: 19434587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements].
    Giménez-Roldán S; Mateo D
    Neurologia; 1989 Oct; 4(8):282-7. PubMed ID: 2534679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders.
    Toglia JU; McGlamery M; Sambandham RR
    J Clin Psychiatry; 1978 Jan; 39(1):81-7. PubMed ID: 147268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases.
    Shen V; Clarence-Smith K; Hunter C; Jankovic J
    Tremor Other Hyperkinet Mov (N Y); 2013; 3():. PubMed ID: 24255799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.
    Huntington Study Group
    Neurology; 2006 Feb; 66(3):366-72. PubMed ID: 16476934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. deutetrabenazine for the treatment of chorea associated with Huntington's disease.
    Gupta H; Perkins W; Stark C; Kikkeri S; Kakazu J; Kaye A; Kaye AD
    Health Psychol Res; 2022; 10(5):36040. PubMed ID: 35774908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural elucidation of two photolytic degradation products of tetrabenazine.
    Bourezg Z; Cartiser N; Ettouati L; Guillon J; Lacoudre A; Pinaud N; Le Borgne M; Fessi H
    J Pharm Biomed Anal; 2014 Mar; 91():138-43. PubMed ID: 24457996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea.
    Walters AS; McHale D; Sage JI; Hening WA; Bergen M
    Clin Neuropharmacol; 1990 Jun; 13(3):236-40. PubMed ID: 2141544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha methylparatyrosine and tetrabenazine in movement disorders.
    Lang AE; Marsden CD
    Clin Neuropharmacol; 1982 Dec; 5(4):375-87. PubMed ID: 6130839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM
    Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease.
    Kegelmeyer DA; Kloos AD; Fritz NE; Fiumedora MM; White SE; Kostyk SK
    J Neurol Sci; 2014 Dec; 347(1-2):219-23. PubMed ID: 25456459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Models of hyperkinetic disorders in primates.
    Bezard E
    J Neurosci Methods; 2020 Feb; 332():108551. PubMed ID: 31857131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tetrabenazine Facilitates Exocytosis by Enhancing Calcium-Induced Calcium Release through Ryanodine Receptors.
    de Pascual R; Álvarez-Ortego N; de Los Ríos C; Jacob-Mazariego G; García AG
    J Pharmacol Exp Ther; 2019 Oct; 371(1):219-230. PubMed ID: 31209099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective Analysis of Healthcare Resource Use, Treatment Patterns, and Treatment-related Events in Patients with Huntington's Disease-associated Chorea Initiated on Tetrabenazine.
    Sung VW; Iyer RG; Gandhi SK; Abler V; Davis B; Irwin DE; Anderson KE
    J Health Econ Outcomes Res; 2018; 6(1):15-24. PubMed ID: 32685569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
    Dean M; Sung VW
    Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine.
    Brusa L; Orlacchio A; Moschella V; Iani C; Bernardi G; Mercuri NB
    Mov Disord; 2009 Jan; 24(1):126-9. PubMed ID: 19170197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.
    Podurgiel SJ; Nunes EJ; Yohn SE; Barber J; Thompson A; Milligan M; Lee CA; López-Cruz L; Pardo M; Valverde O; Lendent C; Baqi Y; Müller CE; Correa M; Salamone JD
    Neuroscience; 2013 Oct; 250():507-19. PubMed ID: 23867769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders.
    Sahin T; Yilmaz R; Akbostanci MC
    Parkinsonism Relat Disord; 2020 May; 74():36-37. PubMed ID: 32311641
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.